{
    "2020-10-26": [
        [
            {
                "time": "2021-10-11",
                "original_text": "Eli Lilly antibody drug fails in a COVID-19 study; other studies go on",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "antibody",
                        "drug",
                        "fails",
                        "COVID-19",
                        "study"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2021-10-11",
                "original_text": "Were Hedge Funds Right About Eli Lilly and Company (LLY)?",
                "features": {
                    "keywords": [
                        "Hedge Funds",
                        "Eli Lilly",
                        "Company",
                        "LLY"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "financial services",
                        "investing"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}